BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1030 related articles for article (PubMed ID: 22686345)

  • 21. From preclinical to human--prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example.
    Sinha VK; Snoeys J; Osselaer NV; Peer AV; Mackie C; Heald D
    Biopharm Drug Dispos; 2012 Mar; 33(2):111-21. PubMed ID: 22383166
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs?
    Bouzom F; Ball K; Perdaems N; Walther B
    Biopharm Drug Dispos; 2012 Mar; 33(2):55-71. PubMed ID: 22228149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Whole-body physiologically based pharmacokinetic population modelling of oral drug administration: inter-individual variability of cimetidine absorption.
    Willmann S; Edginton AN; Kleine-Besten M; Jantratid E; Thelen K; Dressman JB
    J Pharm Pharmacol; 2009 Jul; 61(7):891-9. PubMed ID: 19589231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting the oral pharmacokinetic profiles of multiple-unit (pellet) dosage forms using a modeling and simulation approach coupled with biorelevant dissolution testing: case example diclofenac sodium.
    Kambayashi A; Blume H; Dressman JB
    Eur J Pharm Biopharm; 2014 Jul; 87(2):236-43. PubMed ID: 24462791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An update on computational oral absorption simulation.
    Dressman JB; Thelen K; Willmann S
    Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1345-64. PubMed ID: 21939427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A pH-dilution method for estimation of biorelevant drug solubility along the gastrointestinal tract: application to physiologically based pharmacokinetic modeling.
    Gao Y; Carr RA; Spence JK; Wang WW; Turner TM; Lipari JM; Miller JM
    Mol Pharm; 2010 Oct; 7(5):1516-26. PubMed ID: 20715778
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Physiologically based pharmacokinetics (PBPK).
    Espié P; Tytgat D; Sargentini-Maier ML; Poggesi I; Watelet JB
    Drug Metab Rev; 2009; 41(3):391-407. PubMed ID: 19601719
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Application of physiologically based pharmacokinetic modeling in the prediction of pharmacokinetics of bicyclol controlled-release formulation in human.
    Wang B; Liu Z; Li D; Yang S; Hu J; Chen H; Sheng L; Li Y
    Eur J Pharm Sci; 2015 Sep; 77():265-72. PubMed ID: 26116279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utility of PBPK Absorption Modeling to Guide Modified Release Formulation Development of Gaboxadol, a Highly Soluble Compound With Region-Dependent Absorption.
    Kesisoglou F; Balakrishnan A; Manser K
    J Pharm Sci; 2016 Feb; 105(2):722-728. PubMed ID: 26457884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of an integrated in vitro-in silico PBPK (physiologically based pharmacokinetic) model to provide estimates of human bioavailability.
    Cai H; Stoner C; Reddy A; Freiwald S; Smith D; Winters R; Stankovic C; Surendran N
    Int J Pharm; 2006 Feb; 308(1-2):133-9. PubMed ID: 16352407
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary.
    Jamei M; Abrahamsson B; Brown J; Bevernage J; Bolger MB; Heimbach T; Karlsson E; Kotzagiorgis E; Lindahl A; McAllister M; Mullin JM; Pepin X; Tistaert C; Turner DB; Kesisoglou F
    Eur J Pharm Biopharm; 2020 Oct; 155():55-68. PubMed ID: 32781025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates.
    Kortejärvi H; Urtti A; Yliperttula M
    Eur J Pharm Sci; 2007 Feb; 30(2):155-66. PubMed ID: 17187967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology.
    Rostami-Hodjegan A
    Clin Pharmacol Ther; 2012 Jul; 92(1):50-61. PubMed ID: 22644330
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dissolution testing of oral modified-release dosage forms.
    Garbacz G; Klein S
    J Pharm Pharmacol; 2012 Jul; 64(7):944-68. PubMed ID: 22686342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation.
    Tsume Y; Amidon GL
    Mol Pharm; 2010 Aug; 7(4):1235-43. PubMed ID: 20557130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive models for oral drug absorption: from in silico methods to integrated dynamical models.
    Dokoumetzidis A; Kalantzi L; Fotaki N
    Expert Opin Drug Metab Toxicol; 2007 Aug; 3(4):491-505. PubMed ID: 17696801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Abrahamsson B; Brewster M; Brouwers J; Butler J; Carlert S; Dickinson PA; Dressman J; Holm R; Klein S; Mann J; McAllister M; Minekus M; Muenster U; Müllertz A; Verwei M; Vertzoni M; Weitschies W; Augustijns P
    Eur J Pharm Sci; 2014 Jun; 57():342-66. PubMed ID: 23988843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Computer simulation of blood level profiles. Drug liberation from two sustained-release preparations and computer simulation of single- and multiple-dose pharmacokinetics].
    Koch HP
    Pharmazie; 1992 Jul; 47(7):547-52. PubMed ID: 1518902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative prediction of formulation-specific food effects and their population variability from in vitro data with the physiologically-based ADAM model: a case study using the BCS/BDDCS Class II drug nifedipine.
    Patel N; Polak S; Jamei M; Rostami-Hodjegan A; Turner DB
    Eur J Pharm Sci; 2014 Jun; 57():240-9. PubMed ID: 24060671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.
    Poulin P; Jones RD; Jones HM; Gibson CR; Rowland M; Chien JY; Ring BJ; Adkison KK; Ku MS; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Yates JW
    J Pharm Sci; 2011 Oct; 100(10):4127-57. PubMed ID: 21541937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 52.